• 1. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere

Introduction to 2-(1H-Imidazol-2-yl)pyrimidine (CAS No: 627910-87-6)

2-(1H-Imidazol-2-yl)pyrimidine, identified by the Chemical Abstracts Service Number (CAS No) 627910-87-6, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the class of biaryl derivatives, characterized by the presence of both imidazole and pyrimidine moieties linked through an azomethine bond. The structural framework of 2-(1H-imidazol-2-yl)pyrimidine imparts unique electronic and steric properties, making it a versatile scaffold for the development of novel bioactive molecules.

The imidazole ring in 2-(1H-imidazol-2-yl)pyrimidine is a well-documented pharmacophore, frequently found in a wide array of biologically active compounds, including antiviral, antimicrobial, and anticancer agents. The pyrimidine moiety, on the other hand, is another prominent pharmacophore that is extensively employed in drug design due to its ability to interact with biological targets such as enzymes and receptors. The combination of these two heterocyclic systems in 2-(1H-imidazol-2-yl)pyrimidine creates a promising platform for designing molecules with enhanced binding affinity and selectivity.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various therapeutic areas. Among these, kinase inhibitors have been a major focus due to the critical roles that kinases play in numerous cellular processes. 2-(1H-imidazol-2-yl)pyrimidine has been explored as a potential scaffold for kinase inhibition, particularly due to its ability to mimic the transition state of ATP binding in kinase active sites. Several derivatives of this compound have shown promising activity against various kinases, including tyrosine kinases and serine/threonine kinases.

One of the most compelling aspects of 2-(1H-imidazol-2-yl)pyrimidine is its modularity, which allows for facile functionalization at multiple positions on both the imidazole and pyrimidine rings. This flexibility enables medicinal chemists to fine-tune the physicochemical properties and biological activity of derived compounds. For instance, introduction of substituents such as halogens, alcohols, or amines can significantly alter the potency and selectivity of kinase inhibitors based on this scaffold.

Recent advances in computational chemistry have further accelerated the discovery process for 2-(1H-imidazol-2-yl)pyrimidine derivatives. Molecular docking studies combined with quantum mechanical calculations have provided valuable insights into the binding modes of these compounds with target proteins. These computational approaches have not only helped in identifying lead compounds but also in rationalizing structure-activity relationships (SARs). As a result, several novel analogs with improved pharmacokinetic profiles have been designed and synthesized.

The synthesis of 2-(1H-imidazol-2-yl)pyrimidine can be achieved through various synthetic routes, including condensation reactions between imidazole derivatives and pyrimidine carboxylic acid esters or halides. Modern synthetic methodologies have also enabled the preparation of complex derivatives through multi-step sequences involving cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These advanced synthetic techniques have facilitated the rapid exploration of chemical space around this scaffold.

In addition to its applications in kinase inhibition, 2-(1H-imidazol-2-yl)pyrimidine has been investigated for its potential in other therapeutic areas. For instance, some derivatives have demonstrated antiviral activity by inhibiting viral polymerases or proteases. Others have shown promise as antimicrobial agents by targeting bacterial enzymes or interfering with bacterial cell wall synthesis. The broad spectrum of biological activities exhibited by these compounds underscores their significance as versatile pharmacological tools.

The development of novel drug candidates often involves rigorous preclinical testing to evaluate their safety and efficacy. Several derivatives of 2-(1H-imidazol-2-yl)pyrimidine have entered preclinical studies, where they have shown encouraging results in animal models. These studies have provided valuable data on pharmacokinetic parameters, toxicity profiles, and therapeutic efficacy. The successful translation of these findings into clinical trials could pave the way for new treatments targeting various diseases.

Looking ahead, the future prospects for 2-(1H-imidazol-2-yl)pyrimidine are promising, driven by ongoing research efforts aimed at expanding its therapeutic applications. Innovations in drug design methodologies, coupled with advancements in high-throughput screening technologies, are expected to accelerate the discovery pipeline for new derivatives. Furthermore, interdisciplinary collaborations between chemists, biologists, and clinicians will be crucial in translating basic research findings into tangible therapeutic benefits.

In conclusion,(cas no62791087 6) serves as a cornerstone molecule in pharmaceutical research due to its unique structural features and versatile biological activities. Its potential as a scaffold for developing novel drug candidates continues to be explored across multiple therapeutic areas. As our understanding of biological targets progresses and synthetic methodologies evolve,(cas no62791087 6) derived compounds are poised to play an increasingly important role in addressing unmet medical needs.

• 65034-88-0(tris(2-(pyrimidin-2-yl)pyrimidine), dichlororuthenium)
• 199944-24-6(Bipyrimidine)
• 34671-83-5(2,2'-Bipyrimidine)
• 492-98-8(1H,1'H-2,2'-Biimidazole)
• 60681-68-7(TPymT)
• 438554-21-3(PYRIMIDINE, 2-(1H-IMIDAZOL-2-YL)-, HYDROCHLORIDE)
• 718606-27-0(2,2'-BIPYRIMIDINE, HYDROBROMIDE)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)